Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
SPY ETF Climbs 0.4%

SPY ETF Climbs 0.4%

Dow JonesDow Jones2026/08/21 20:37

This article was automatically generated using Dow Jones technology.

Shares of State Street SPDR S&P 500 ETF Trust rose 0.4% to $765.72 Friday on what proved to be an overall favorable trading session for the U.S. stock market, with the S&P 500 Index, the fund's underlying index, rising 0.4% to 7,674.37.

The ETF's shares closed 1.8% below the 52-week high of $779.37 seen on August 13, 2026.

Trading volume was 37,694,246, compared to the 65-day average trading volume of 51,402,379.

As of August 20, the fund's net asset value totaled $762.24 per share.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

August 21, 2026 16:37 ET (20:37 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The second wave of energy price increases is looming! European Central Bank’s Lane warns: eurozone inflation will be higher and more persistent

Philip Lane, Chief Economist of the European Central Bank, stated that a new round of high energy prices means inflation in the eurozone will remain elevated for longer than the ECB initially anticipated.

智通财经2026/09/22 07:56

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions

ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.

智通财经2026/09/22 07:21

Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.

The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.

智通财经2026/09/22 07:11